The depth and breadth of Antisense Therapeutics' clinical/non-clinical data has increased substantially over the past 24 months, points out Morgans. 

With additional animal and human plasma studies expected to drive a better understanding into the mechanism of action (MOA) and new indications, it's beginning to look like a compelling package, notes the broker.

The analyst is buoyed by recent events, including information on new indications and preliminary feedback from the two major regulatory authorities, and a FDA fast-track submission. The target price increases to $0.44 from $0.38.

Sector: Pharmaceuticals, Biotechnology & Life Sciences.

Target price is $0.44.Current Price is $0.21. Difference: $0.23 - (brackets indicate current price is over target). If ANP meets the Morgans target it will return approximately 52% (excluding dividends, fees and charges - negative figures indicate an expected loss).

© 2021 Acquisdata Pty Ltd., source FN Arena